Management of Elevated Bilirubin in Heart Failure

Guideline-Directed Medical Therapy

The American College of Cardiology recommends continuing guideline-directed medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists) unless hemodynamically unstable or contraindicated 1, 2, 3
Measure blood pressure, heart rate, and assess for signs of hypoperfusion (cool extremities, altered mental status, oliguria) 1
Check serum electrolytes, renal function (BUN, creatinine), and liver enzymes alongside bilirubin 1, 2

Administer intravenous loop diuretics at doses at least equivalent to (or greater than) the patient's chronic oral daily dose 1, 2
For patients not on chronic diuretics, start with furosemide 20-40 mg IV (or equivalent) 1
Give as intermittent boluses or continuous infusion, adjusting based on urine output and clinical response 1, 2
Monitor urine output, daily weights, symptoms, renal function, and electrolytes during titration 1, 2

Reserve inotropes for documented hypotension or hypoperfusion, as they carry safety concerns 2
The European Heart Society suggests that inotropes should not be used indiscriminately in all decompensated patients 2

Daily weights - Target 0.5-1 kg loss per day until euvolemia achieved 3
Renal function and electrolytes - Check during diuretic titration to detect worsening renal function or electrolyte derangements 1, 2
Clinical congestion signs - Jugular venous pressure, peripheral edema, pulmonary rales 1

Schedule follow-up within 7-14 days of discharge, with telephone contact within 3 days 1
Enroll in multidisciplinary heart failure disease-management program to reduce readmission and mortality 1, 3
Optimize chronic oral heart failure medications (ACE inhibitors, beta-blockers, aldosterone antagonists) 1, 3
Educate on daily weight monitoring, sodium/fluid restriction, symptom recognition, and when to contact providers 1, 3
Recheck liver function tests, renal function, and electrolytes at first outpatient visit 1